Surgery Partners, Inc. (SGRY) stock

SGRYNasdaqServices-General Medical & Surgical Hospitals, NECFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 5/308% above fair value

$26.95+0.37 (+1.39%)

Close on Nov 13, 2026Market cap $3.53BP/E –Yield –

Surgery Partners r&d expenses

Research and development expenses are spending on new products and technology.

Surgery Partners has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Surgery Partners's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SGRY.

Revenue growth2.2% · median 2.0%

Operating margin10.8% · median 10.9%

Net margin-2.6% · median 5.0%

Advertisement
300 × 250

See a number that looks wrong?